Decision Support in Delaware

Amalgam Rx is a regulated digital health company specializing in Software as a Medical Device (SaMD) development. Founded in 2016 and based in Wilmington, Delaware, the company develops AI-powered, modular SaaS platforms that integrate seamlessly with electronic health records (EHR) to enhance clinical decision-making across chronic care ecosystems. The company's Medical-Grade AI™ technology supports patient identification for clinical trials, clinical decision support, digital therapeutics (DTx), caregiver engagement, and wearable device integration. Amalgam Rx's platform has facilitated over 70 million clinical decisions and currently supports nearly 10 million patients across four continents with regulatory clearance. The company partners with life sciences organizations, health plans, and healthcare providers to deliver point-of-care solutions including care guidelines, financial assistance programs, and companion products. With demonstrated FDA expertise and Manufacturer of Record (MOR) designation, Amalgam Rx emphasizes regulatory compliance, quality management systems, and global scalability across multiple markets.

Vistim Labs develops Ceregram, a patented Evoked Potential Tomography (EPT) technology for non-invasive, radiation-free neurological monitoring. The platform is designed to track disease progression in dementia patients (Alzheimer's, Parkinson's, Lewy Body Disease) and other neurological disorders by localizing and quantifying sensory deficits caused by neurodegeneration. Ceregram monitors across multiple disease endpoints including brain volume changes, physiological markers (amyloid and tau accumulation), and psychological/cognitive performance metrics (MMSE, CERAD, TASIT). The technology enables point-of-care evaluation in office-based clinical settings, allowing physicians to assess treatment response and adjust disease management in real time without requiring PET imaging or other advanced neuroimaging. The company has published peer-reviewed research in Alzheimer's Research and Therapy Journal and presented findings at major conferences including the American Academy of Neurology (2025) and Alzheimer's Association International Conference (2023). Ceregram is positioned as a clinical decision-support tool for cognitive monitoring and is not intended as a diagnostic device or replacement for PET, MRI, or other imaging modalities. The company operates with offices in Miami and San Diego, with affiliate locations in New York, Paris, and Berlin. Vistim Labs has participated in biotech accelerators (PharmStars, Boston) and won multiple startup pitch competitions.